Acrivon Therapeutics, Inc. (ACRV)

Acrivon Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020
Cash & Equivalents	36.43	29.91	99.99	1.99
Short-Term Investments	91.44	98.23	0	0
Cash & Cash Equivalents	127.87	128.14	99.99	1.99
Cash Growth	-0.21%	28.15%	4924.67%	-
Other Current Assets	1.82	3.96	0.42	-0.27
Total Current Assets	129.69	132.1	100.41	1.72
Property, Plant & Equipment	7.91	6.86	5.79	0.06
Long-Term Investments	0	41.88	0	0
Other Long-Term Assets	0.67	0.39	0.39	0.41
Total Long-Term Assets	8.57	49.13	6.18	0.47
Total Assets	138.27	181.23	106.59	2.19
Accounts Payable	5.05	0.9	0.96	0.14
Current Debt	0.88	0.73	0.66	0
Other Current Liabilities	7.38	4.89	1.29	0.48
Total Current Liabilities	13.3	6.52	2.91	0.61
Long-Term Debt	3.77	4.24	4.96	0
Other Long-Term Liabilities	0	0	0	0.32
Total Long-Term Liabilities	3.77	4.24	4.96	0.32
Total Liabilities	17.07	10.75	7.88	0.93
Total Debt	4.64	4.96	5.63	0
Debt Growth	-6.39%	-11.85%	-	-
Retained Earnings	-116.42	-56.03	-24.87	-8.62
Comprehensive Income	-0.08	-0.1	0	0
Shareholders' Equity	121.2	170.48	-23.81	-8.41
Net Cash / Debt	123.23	123.18	94.36	1.99
Net Cash / Debt Growth	0.04%	30.54%	4641.86%	-
Net Cash Per Share	5.58	29.88	54.13	1.39
Working Capital	116.39	125.58	97.49	1.11
Book Value Per Share	5.49	41.36	-13.66	-5.87

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).